Genetic and Molecular Characterization of Nervous System Lesions
Condition(s) studied
Investigational drug(s) / intervention(s)
Prospective Biological Collection: All samples that can be collected at each visit : * Saliva sampling (added by the research) * Collection of 2 to 4 additional tubes of blood (maximum 56mL) (added by the research if blood sampling in routine care) * Urine and stool samples (added by the research) * CSF sample residues (added by the research if lumbar punction in routine care) * Lesion sample residues and surgical waste fragments (added by the research if surgery in routine care)
Retrospective Biological Collection: Requalification of all biological samples obtained as part of ONCONEUROTEK research, with patient consent (blood, saliva, urine, Stool, CSF, lesion sample and surgical waste fragments)
Study summary
Primary and secondary brain tumors, the leading cause of death from cancer before the age of 35, represent a complex and heterogeneous group of pathologies with a generally poor prognosis. Knowledge of these tumors has made enormous strides thanks to access to biological samples, leading to a much more robust, reliable and precise histo-pronostic classification, but also, increasingly, to the identification of theranostic targets.
Despite these advances, there is a real need to refine diagnostic and prognostic classification, identify the biological mechanisms involved in the formation and progression of these pathologies, develop new targeted strategies, and devise minimally invasive follow-up methods (liquid biopsies).
In addition, certain non-tumoral brain lesions (e.g. malformations) can be similarly classified according to their molecular and mutational profile.
This project aims to make a decisive contribution to these objectives.
Eligibility
Primary outcome measure(s)
- Study the clinical markers with the evolution of brain lesions. — 10 years
Study of patients' disease-related data in their medical records - Study the biological markers with the evolution of brain lesions. — 10 years
Study blood, saliva, urine, stool and CSF samples - Study the anatomopathological markers with the evolution of brain lesions. — 10 years
Study of cerebral lesion tissues
Trial sites (3)
| Facility | City | Region | Status |
|---|---|---|---|
| Service de Neurochirurgie - Hôpital de la Pitié Salpêtrière | Paris | France | Recruiting |
| Service de Neurologie 2 -Hôpital de la Pitié Salpêtrière | Paris | France | Recruiting |
| Service de Radiothérapie - Hôpital de la Pittié Salpêtrière | Paris | France | Recruiting |
More Assistance Publique - Hôpitaux de Paris trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06314607 on ClinicalTrials.gov ↗ ← All trials in France